** Shares of Danaher rise 1.7% to $243.86 premarket
** Life sciences co said on Monday it expects Q4 revenue to increase in low-single digit percent range year-over-year
** Preliminary results indicate continued but expected recovery in co's bioprocessing unit, brokerage Leerink Partners says
** "We continue to see DHR as a sector leader and an M&A compounder/operator with a market-leading franchise in bioprocessing," Leerink says
** DHR fell 0.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.